TICKERNERD
Menu
ENOVENOVHealthcare · Medical Devices

ENOV Stock Forecast: Enovis Corp. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$18
0.00% on the day

The 13 Wall Street analysts covering Enovis Corp. hold a median 12-month price target of $37 — +102.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.0B
Ticker Nerd rank
80 / 100
Median analyst target
$37
Analysts covering
13
Revenue$582.8M+3.2% y/y
Operating income$22.3M
Net income−$1.0M
Free cash flow$31.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.0%
1M
−30.8%
YTD
−32.3%
1Y
−44.3%
From 52W high
−45.1%
From 52W low
+1.3%
$18
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENOV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enovis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Accruals
97
Issuance
78
Growth
77
Quality
60
Revisions
50
Size
44
Volatility
41
Momentum
21

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (21): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENOV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENOV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50Oct 25Jan 26Apr 26Jul 26ENOVHigh $52Median $37Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
12 Buy1 Hold0 Sell
Low $24Median $37High $52

The green dot is the last close — the median target sits +102.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
2 Sept 2026CitizensMaintainsMarket Outperform$55 → $47
2 Sept 2026Freedom Capital MarketsMaintainsBuy$41 → $36
2 Sept 2026Wells FargoMaintainsOverweight$39 → $33
1 Sept 2026BTIGMaintainsBuy$40 → $36
17 Aug 2026Canaccord GenuityMaintainsBuy—
17 Aug 2026Canaccord GenuityMaintainsBuy$50 → $45
7 Aug 2026Wells FargoMaintainsOverweight—
7 Aug 2026Wells FargoMaintainsOverweight$40 → $39
6 Aug 2026BTIGMaintainsBuy—
6 Aug 2026BTIGMaintainsBuy$39 → $40
28 July 2026UBSAssumesBuy$50 → $51
9 July 2026BMO CapitalInitiatesOutperform$29
9 July 2026BMO CapitalInitiatesOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$36 → $32
6 July 2026Evercore ISI GroupMaintainsOutperform—
22 May 2026BTIGReiteratesBuy—
8 May 2026Evercore ISI GroupMaintainsOutperform—
8 May 2026Wells FargoMaintainsOverweight—
17 Apr 2026William BlairAssumesOutperform—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENOV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ENOV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, Enovis Corp. returned −44.3% against +17.8% for the S&P 500, dividends included.

ENOV vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Oct 25Jan 26Apr 26Jul 26ENOVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENOV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.2%
Analysts raising
5
Analysts cutting
5
Fundamentals

Enovis Corp. (ENOV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
0.5×

Cheaper than 83% of US stocks

Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
6.3×

Cheaper than 50% of US stocks

Growth & margins
Revenue growth (YoY)
3.2%

Higher than 35% of US stocks

Earnings growth (YoY)
3.2%

Higher than 40% of US stocks

Gross margin
61.6%

Higher than 75% of US stocks

Operating margin
4.2%

Higher than 53% of US stocks

Net margin
−48.0%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−54.1%

Higher than 20% of US stocks

Return on assets
1.2%

Higher than 52% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Enovis Corp. (ENOV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enovis Corp. has a market value of $1.0B and an enterprise value of $2.4B.

  • Revenue in the twelve months to 30 June 2026: $2.3B. The latest quarter grew 3.2% year on year.

  • Net income over the same four quarters: −$1.1B, a −47.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−19.26.

  • Free cash flow in the twelve months to 30 June 2026: $63.7M.

  • Shares outstanding: 57.7M.

  • Trailing P/E: −0.9×; forward P/E: 4.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Enovis Corp. employs 7,802 people — $294K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Sept 2026

Data provided by Twelve Data

Peers

ENOV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ENOVEnovis Corp.$1.0B
80
LMRILumexa Imaging Holdings, Inc.$1.0B
1
IRMDIRadimed Corp.$1.1B
89
BVSBioventus, Inc.$1.1B
98
PRCTPROCEPT BioRobotics Corp.$1.1B
38
AORTArtivion, Inc.$1.1B
41
BBNXBeta Bionics, Inc.$1.2B
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enovis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENOV news & analysis

Insider at Medical Device Maker Buys More Than 7,500 Shares

The Motley Fool · 14 Sept 2026neutral

A medical device company insider purchased 7,598 shares at a weighted average price of $19.74 per share, for a total investment of roughly $150,000. The transaction represented about 14% of the executive's prior equity stake in the company.

Why it matters — An executive increasing their stake can signal insider confidence in the company, which is notable for Enovis Corp. watchers monitoring insider activity.

What Makes Enovis (ENOV) a New Buy Stock

Zacks Investment Research · 3 Sept 2026positive

Enovis (ENOV) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade is expected to support the stock's performance in the near term.

Why it matters — The upgrade signals increased analyst confidence in Enovis's earnings outlook, which a stock watcher would weigh when assessing the company's recent momentum.

Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research · 3 Sept 2026neutral

Enovis (ENOV) has become technically oversold after losing 33% over four weeks, which analysts suggest may indicate exhaustion of selling pressure. Wall Street analysts have also been revising earnings estimates higher, together pointing to a potential near-term trend reversal for the stock.

Why it matters — For Enovis watchers, the combination of oversold technical conditions and rising earnings estimate revisions could signal a possible turning point after the stock's sharp decline.

Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition

Zacks Investment Research · 2 Sept 2026neutral

Enovis (ENOV) plans to acquire eCential Robotics to expand into orthopedic surgical robotics. The deal is expected to pressure the company's 2027 margins.

Why it matters — A ENOV watcher would care because the acquisition broadens the company's surgical robotics portfolio, although its anticipated impact on 2027 margins is a factor to monitor.

Enovis Corporation (ENOV) M&A Call Transcript

Seeking Alpha · 1 Sept 2026neutral

Enovis Corporation held a merger-and-acquisition call, the transcript of which was published by Seeking Alpha. The call covered M&A-related discussion for the company.

Why it matters — ENOV watchers would care because the transcript provides insight into the company's merger-and-acquisition activity and related strategic discussions.

FAQ

Frequently asked questions about ENOV stock

What is the ENOV stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Enovis Corp. have a median 12-month price target of $37, with estimates ranging from $24 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENOV stock a buy right now?

Of the 13 analysts covering Enovis Corp., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enovis Corp. 80 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENOV?

As at 19 Sept 2026, Enovis Corp. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will ENOV stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +102.3% from the last close, and Ticker Nerd's factor model ranks Enovis Corp. 80 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENOV stock forecast for 2030?

No analyst covering Enovis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $52 over the next 12 months.

How has ENOV stock performed over the past year?

Enovis Corp. returned -44.3% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enovis Corp. do?

Enovis Corporation is a medical technology company focused on developing clinically differentiated solutions for musculoskeletal health. Enovis Corporation designs, manufactures, and distributes medical devices and services used across the patient care continuum, including injury prevention, rehabilitation, pain management, physical therapy, and reconstructive surgery.

What is the latest news on ENOV?

The most recent item we track (The Motley Fool, 14 Sept 2026): "Insider at Medical Device Maker Buys More Than 7,500 Shares". A medical device company insider purchased 7,598 shares at a weighted average price of $19.74 per share, for a total investment of roughly $150,000. The transaction represented about 14% of the executive's prior equity stake in the company.

Company

About Enovis Corp.

Enovis Corporation is a medical technology company focused on developing clinically differentiated solutions for musculoskeletal health. Enovis Corporation designs, manufactures, and distributes medical devices and services used across the patient care continuum, including injury prevention, rehabilitation, pain management, physical therapy, and reconstructive surgery. Its product portfolio includes orthopedic braces and supports, recovery and rehabilitation technologies, joint replacement implants, and surgical enabling tools that support hip, knee, shoulder, elbow, foot, ankle, and other extremity procedures. The company serves healthcare professionals and patients through two main business segments, Prevention & Recovery and Reconstructive, reflecting its role in both non-surgical treatment and surgical care. Enovis Corporation operates in the orthopedic and broader medical device markets, where it provides solutions intended to improve mobility, restore function, and support clinical workflows across hospitals, outpatient settings, and other care environments.

CEO Mr. Damien McDonald · 7,802 employees · United States · https://www.enovis.com